(Q36289356)

English

Risk management strategies in the postmarketing period : safety experience with the US and European bosentan surveillance programmes

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

1 reference

Europe PubMed Central

Risk management strategies in the postmarketing period : safety experience with the US and European bosentan surveillance programmes (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

author name string

Eleanor S Segal

1

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Cecile Valette

2

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Laurence Oster

3

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Luc Bouley

4

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Catarina Edfjall

5

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Peter Herrmann

6

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Massimo Raineri

7

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Mary Kempff

8

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Saundra Beacham

9

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Cinda van Lierop

10

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

971-980

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Risk assessment of drugs, biologics and therapeutic devices: present and future issues

1 reference

https://pubmed.ncbi.nlm.nih.gov/16231952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endothelin receptor antagonists in pulmonary arterial hypertension.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16231952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary pulmonary hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/16231952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacoepidemiology: current status, prospects, and problems

1 reference

https://pubmed.ncbi.nlm.nih.gov/16231952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint

1 reference

https://pubmed.ncbi.nlm.nih.gov/16231952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of pulmonary arterial hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/16231952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

1 reference

https://pubmed.ncbi.nlm.nih.gov/16231952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16231952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bosentan therapy for pulmonary arterial hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/16231952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16231952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug-induced liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/16231952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postmarketing surveillance--lack of vigilance, lack of trust.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16231952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16231952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival with first-line bosentan in patients with primary pulmonary hypertension.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16231952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00002018-200528110-00001

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36289356&oldid=2198562821"